一项前瞻性、多中心、单臂、上市后观察研究,以评估阿基米德可生物降解胆道和胰腺支架的安全性和临床性能 (Registry)
Significant experience with biodegradable materials has been reported in the orthopedic literature; in particular; biodegradable stents have been used in the endovascular and urologic epithelium. Stents are typically made from polymeric materials including Polylactic Acid (PLA), Polyglycolide (PGA), Polydioxanone (PDO), Polyethyleneglycol (PEG), Polycaprolactone (PCL), etc., which have been cleared or approved by the FDA and CE-marked as drug carriers, sutures, and bone fixatives. The material is degraded by hydrolysis in, e.g., lactic acid, which is removed from the body by normal metabolic pathways. In the field of gastroenterology, these stents were first introduced in patients with an esophageal stenosis with encouraging results, although esophageal hyperplasia was a frequently encountered complication.
For biliary applications, biodegradable stents have been evaluated in several in-vitro and animal studies that demonstrated that the stents were safe and well tolerated. These stents provided an adequate radial force and resulted in complete stricture resolution within several months. The stents did not show any signs of biliary hyperplasia or integration in the epithelium. Moreover, they seem to have a self-clearing effect on attached biofilm as the outer layer sloughs during the degradation process similarly to the exfoliation of human skin. Also, the stent could be removed from the bile duct, thus offering the possibility of extraction if necessary at various times after implantation.
In 2010, Petryl was the first to use a biodegradable stent in the human bile duct. A stent was successfully placed using percutaneous transhepatic cholangiograpy in two patients with a postsurgical intrahepatic biliary stricture. Transient cholangitis was the only complication encountered and during the two years of follow-up, the bile duct remained patent.
Later, Mauri et al. presented in 2013 and 2016 results of a 107 patient study on a polydioxanone biodegradable biliary stent. The results have been published in the Journal of the European Society of Radiology. The authors concluded that percutaneous placement of a biodegradable biliary stent is a feasible and safe strategy to treat benign biliary strictures refractory to standard bilioplasty, with promising results in the mid-term period.
Prior to this study, the ARCHIMEDES device was assessed in the ARCHIMEDES Investigational study which has completed enrolment with 53 patients included, and the results are not yet published. In this study approximately half the stents were deployed in the bile duct (53%) and half in the pancreatic duct. All 53 patients have either completed, exited, or no longer have the study device. No patient remains in the study with a stent in place during the time of the last patient follow-ups. The study concluded without any device-related SAE. Bilirubin was reduced by 25.6%, which exceeded the >20% clinical success criterion, quality of life score improved from 3.7 to 7.9, procedural success was rated 1.4 (good to excellent), and technical success was achieved in all 53 patients.
Data from the ARCHIMEDES Investigational study was used for CE Mark approval, which was obtained in June 2018.
研究概览
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:NIta Gondaliya
- 电话号码:+49 1716578285
- 邮箱:ngondaliya@q3medical.com
研究联系人备份
- 姓名:Manfred Guelcher
- 电话号码:+4941716578200
- 邮箱:mguelcher@q3medical.com
学习地点
-
-
-
Afula、以色列、1834111
- 完全的
- Emek Medical Center
-
-
-
-
-
Düsseldorf、德国、40217
- 招聘中
- Evangelisches Krankenhaus Düsseldorf
-
接触:
- Biljana Dimitrijevic, PhD
- 电话号码:+49 (0)211919483 601
- 邮箱:Biljana.Dimitrijevic@evk-duesseldorf.de
-
接触:
- Carina Friesl
- 邮箱:carina.friesl@evk-duesseldorf.de
-
首席研究员:
- Dr. Thomas Veiser, PhD
-
-
-
-
-
Forlì、意大利、47121
- 完全的
- AUSL Romagna Ospedale Morgagni - Pierantoni
-
Pavia、意大利、27100
- 主动,不招人
- Gastroenterology and Digestive Endoscopy Unit Fondazione I.R.C.C.S. Policlinico San Matteo
-
Roma、意大利、00128
- 主动,不招人
- UCBM - Campus Bio-Medico University
-
-
Milano
-
Rozzano、Milano、意大利、20089
- 主动,不招人
- Endoscopy Unit, Humanitas Research Hospital
-
-
-
-
-
Ljubljana、斯洛文尼亚、1000
- 招聘中
- University Medical Center Ljubljana
-
接触:
- Karin Pulevic, VS
- 电话号码:+38615228515
- 邮箱:karin.pulevic@kclj.si
-
接触:
- Dr. Martina Jaklič, MD
- 电话号码:+38615222037
- 邮箱:martina.jaklic@kclj.si
-
首席研究员:
- Dr Samo Plut, MD
-
-
-
-
-
Singapore、新加坡、308433
- 完全的
- Tan Tock Seng Hospital Pte Ltd,
-
-
-
-
-
Paris、法国、75015
- 主动,不招人
- Hôpital Européen Georges-Pompidou HEGP Service d'Hépato-gastro-entérologie et endoscopies digestives
-
-
-
-
-
Helsinki、芬兰、00290
- 完全的
- HUS Helsinki University Hospital
-
-
-
-
-
Salamanca、西班牙、37007
- 招聘中
- Hospital Universitario de Salamanca
-
接触:
- Solorzano Garcia Ignacio
- 电话号码:55400 +34 679441022
- 邮箱:isolorzano.ibsal@saludcastillayleon.es
-
首席研究员:
- Dr. Alberto Álvarez Delgado, MD, PhD
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Patients that will respect the inlcusion criteria will be enrolled in the study.
描述
Inclusion Criteria:
- Patient eligible for implantation of a pancreatic or billiary stent prior to participate in the study and according to current guidelines
- Patient has provided a signed and dated informed consent (according to the laws and regualtions of the country in which the observational study is conducted)
Exclusion Criteria:
- Age < 18 y
- Inability to understand the purpose of the study or refusal to cooperate
- Not available for routine follow-up visits
- Pregnancy
- Currently participating in a confounding trial before reaching first endpoint.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Patients will treated with ARCHIMEDES Biodegradable Biliary and Pancreatic Stent in routine practice
Participants receiving commercially available ARCHIMEDES Biodegradable Biliary and Pancreatic as part of standard care. Safety outcomes are collected for post-marketing surveillance |
Patients will treated with ARCHIMEDES Biodegradable Biliary and Pancreatic Stent in routine clinical practice |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Primary Safety endpoint
大体时间:From enrollment to the end of treatment, as per the standard of care.
|
Proportion of subjects experiencing procedure- or device-related complications within 30 days including Post-ERCP pancreatitis, Bleeding, Perforation (biliary/pancreatic/duodenal), Stent misplacement, Stent migration, Biliary occlusion, Cholangitis, Severe pain, All-cause death Within 30 days of the index procedure |
From enrollment to the end of treatment, as per the standard of care.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Secondary endpoints are defined as:
大体时间:Technical and Procedural success on the Procedure day and clinical success as per the Standard of Care
|
Clinical success: patency rate as defined by the rate of freedom of stent replacements at follow-up time points defined by investigators definition of SOC (standard of care) or until planned bridge surgery (defined as no need of stent replacement). Technical success: Accurate stent deployment across the target stricture as evaluated by fluoroscopy and endoscopy. Procedural success will be quantified (using a dedicated score system, Excellence=1, Good=2, Fair=3, Poor=4) by the endoscopist post procedure using the following components:
|
Technical and Procedural success on the Procedure day and clinical success as per the Standard of Care
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- QM-NI-ABS-034
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.